Tango Therapeutics shows strong pancreatic cancer trial results despite market sell-off.

Tango Therapeutics reported an 82% overall response rate in a trial for MTAP-deleted/RAS-mutant pancreatic cancer, outperforming historical data. Despite a sell-off after their ESMO presentation, the company maintains a strong cash position of $1 billion and a trial design aligned with FDA requirements. Their drug vopimetostat reduces toxicity and cost when combined with daraxonrasib, positioning Tango as a preferred partner for RAS-targeted therapies. Key risks include supply issues and toxicities, but the company's financial strength and reduced competition support a positive outlook.

Tango Therapeutics shares are currently priced at USD 22.41 on Pluang, down 2.10% in the last day. As of Oct 29, 2026 03:21 WIB, the stock holds a market cap of $3.86 billion with a typical hold time of 2 days on the platform.